Compare Amgen, Inc. (AMGN) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs McCormick & Company, Incorporated — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while McCormick & Company, Incorporated trades at $52.45 (market cap $14.08B). The key difference: Amgen, Inc. is far larger — about 13.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.66%). Which is the better fit depends on your goals.
| AMGN | MKC | |
|---|---|---|
Market Cap | $196.12B | $14.08B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $72.81 |
52-Week Low | $271.18 | $45.60 |
Enterprise Value | $241.41B | $18.68B |
Dividend Yield | 2.77% | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
McCormick (MKC) trades at $52.45, up 1.77% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, supported by a transformative $45 billion Unilever Foods deal announced in July 2026. Valuation appears attractive with a P/E of 8.73, below industry averages, while cash flow trends indicate robust operational performance.
The outlook is mixed; analyst consensus targets $59.67 (14% upside) with a 'Hold' bias, but weak consumer volume growth and integration risks from the Unilever acquisition pose challenges. The stock offers a near 4% dividend yield, providing income support, yet execution on cost savings and volume recovery remains critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
